Fluoxetine (Prozac): Clinical Overview
Fluoxetine is FDA-approved for major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, premenstrual dysphoric disorder, panic disorder, and bipolar disorder (in combination with olanzapine), with specific dosing that varies by indication and patient age. 1
FDA-Approved Adult Indications
Fluoxetine has the following approved uses 1:
- Major Depressive Disorder (MDD)
- Obsessive-Compulsive Disorder (OCD)
- Bulimia Nervosa
- Panic Disorder
- Premenstrual Dysphoric Disorder
- Bipolar Depression (combined with olanzapine)
Notably, fluoxetine is the only antidepressant FDA-approved for major depression in children/adolescents aged 8 years or older 1.
Adult Dosing Regimens
Major Depressive Disorder
Start with 20 mg once daily in the morning 2. This dose is sufficient for most patients, as studies demonstrate 20 mg/day achieves satisfactory response in the majority of cases 2.
- Initial dose: 20 mg/day (morning)
- Dose adjustment: May increase after several weeks if insufficient improvement
- Maximum dose: 80 mg/day
- Dosing schedule: Once daily (morning) or BID (morning and noon) for doses >20 mg 2
- Time to full effect: 4 weeks or longer 2
Maintenance treatment: Continue for at least 4-9 months after satisfactory response for first episode; longer duration for recurrent depression 3, 2. Efficacy maintained up to 38 weeks at 20 mg/day 2.
Obsessive-Compulsive Disorder
Higher doses are typically required for OCD 1, 2:
- Initial dose: 20 mg/day (morning)
- Target dose range: 20-60 mg/day
- Maximum dose: 80 mg/day (well-tolerated in open studies)
- Time to full effect: 5 weeks or longer 2
- Dose escalation: Consider increasing after several weeks if insufficient improvement
A 2010 meta-analysis demonstrated superior efficacy with higher dosing (60-80 mg) compared to lower doses for OCD 1.
Bulimia Nervosa
For bulimia, the recommended dose is 60 mg daily 4:
- This is higher than the typical starting dose for depression
- Represents the evidence-based effective dose for this indication
Special Populations
Hepatic Impairment
Use lower or less frequent dosing 2. Fluoxetine metabolism is affected by liver disease, requiring dose reduction.
Renal Impairment
Dosage adjustments are not routinely necessary 2.
Elderly Patients
Consider lower or less frequent dosing 2. Paroxetine and fluoxetine should generally be avoided in older adults due to higher rates of adverse effects; when used, start conservatively 5.
Patients on Multiple Medications
Reduce dose or frequency due to potential drug interactions 2.
Contraindications
Absolute Contraindications
Concomitant use with MAOIs is absolutely contraindicated 6, 2:
- At least 14 days must elapse between discontinuing an MAOI and starting fluoxetine
- At least 5 weeks (or longer) must elapse after stopping fluoxetine before starting an MAOI 2
- This extended washout reflects fluoxetine's long half-life (1-3 days for parent compound, 7-15 days for active metabolite norfluoxetine) 7
Major Warnings
Black box warning for treatment-emergent suicidality, particularly in adolescents and young adults 1.
Drug Interactions and Monitoring
Critical Drug Interactions
Fluoxetine is metabolized through CYP2D6 and affects multiple cytochrome P450 pathways 1, 8:
- CYP2D6 interactions: Fluoxetine, paroxetine, and sertraline may interact with drugs metabolized by CYP2D6 6
- Serotonin syndrome risk: Avoid combining with other serotonergic drugs, especially MAOIs, tramadol, meperidine, fentanyl, dextromethorphan, St. John's wort, and illicit drugs (MDMA, methamphetamine) 6
- TCA interactions: When switching to tricyclic antidepressants, TCA doses may need reduction and plasma levels monitored 2
Pharmacogenetic Considerations
CYP2D6 and CYP2C19 genetic variation affects fluoxetine metabolism 1, 8. While pharmacogenetic testing can guide dosing, it is not required for routine prescribing. Poor metabolizers may experience higher drug levels and increased adverse effects.
Monitoring Recommendations
Assess patient status, therapeutic response, and adverse effects regularly beginning within 1-2 weeks of initiation 3:
- Initial assessment: 1-2 weeks after starting
- Efficacy evaluation: Do not assess before 4 weeks for depression 2 or 8 weeks for OCD 9
- Dose modification: If inadequate response after 6-8 weeks, modify treatment 3
- Cardiac monitoring: Not routinely required (unlike citalopram which can prolong QT interval) 6
- Suicidality monitoring: Particularly important in adolescents and young adults
Adverse Effects Profile
Common Adverse Effects 6, 5, 10
- Nausea (most common reason for discontinuation)
- Insomnia
- Nervousness/anxiety
- Headache
- Sexual dysfunction
- Asthenia (weakness)
- Somnolence
- Decreased libido
Notably, insomnia or nervousness at treatment start may predict good response 9.
Serious Adverse Effects
Serotonin syndrome 6: Mental status changes, neuromuscular hyperactivity (tremors, clonus, hyperreflexia), autonomic hyperactivity (hypertension, tachycardia, diaphoresis). Symptoms arise within 24-48 hours of combining serotonergic medications. Advanced symptoms include fever, seizures, and unconsciousness requiring hospitalization.
Abnormal bleeding: Especially with concomitant NSAIDs or aspirin 6.
Discontinuation Syndrome
Fluoxetine has the lowest risk of discontinuation syndrome among SSRIs due to its long half-life 6, 7. Paroxetine, fluvoxamine, and sertraline have higher risk. Symptoms include dizziness, fatigue, myalgias, nausea, insomnia, anxiety, and sensory disturbances.
Safety in Overdose
Fluoxetine is significantly safer in overdose compared to tricyclic antidepressants 7. It does not affect cardiac conduction or cause orthostasis at therapeutic doses 7.
Clinical Pearls
Activation vs. Sedation
Fluoxetine has activating properties 6, 10. A meta-analysis found significant change in sedation but not activation compared to placebo 10. This makes morning dosing preferable and may benefit patients with apathy or psychomotor retardation.
Efficacy Considerations
All second-generation antidepressants are equally effective for treatment-naive patients 5. Medication choice should be based on adverse effect profiles, cost, and patient preferences 3, 5.
Antidepressants are most effective in patients with severe depression 5. The number needed to treat ranges from 7-16 for tricyclics and 7-8 for SSRIs 5.
Switching Strategies
When switching from fluoxetine to another antidepressant, allow at least 5 weeks washout before starting an MAOI 2. For other antidepressants, the long half-life provides natural tapering, reducing withdrawal risk 11.